RxDoctor Payments Data

Tara Pemberton, PA

Medical · Portland, ORNPI 1275803462

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,955 of the $2,206 with a category attached, or 88.6%. It is spread thinly across 19 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $919, 7.3 times the $126 reported in 2021.

$2,206in general payments, 2019–2025

Across 89 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$440
  • Sanofi$435
  • Regeneron Healthcare Solutions, Inc.$318
  • AbbVie$143
  • Biocryst US Sales Co., LLC$143
  • GSK$102
  • plus $626 from 13 others

What the payments were for

  • Food & beverage$1,95589%
  • Education$25211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,206 in reported general payments places this provider in the 85th percentile of 364 medical providers in Oregon.

See all medical providers in Oregon

Medicare billing

Part B allowed, 2024
$41,706
Medicare patients
52
Services billed
1,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab18$50,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,964
Qvar RedihalerBeclomethasone Dipropionate18$9,975
Breo ElliptaFluticasone/Vilanterol15$5,768
Advair HfaFluticasone Propion/Salmeterol11$4,587
Arnuity ElliptaFluticasone Furoate14$3,600
Albuterol Sulfate HfaAlbuterol Sulfate18$731
Azelastine Hcl22$557
Montelukast Sodium36$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$102$25,33150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 364 medical providers in Oregon.

Other medical in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →